Phillip Longman is senior editor of the Washington Monthly.
Phil joined the staff of the Washington Monthly in 2012. He is also the policy director at the Open Markets Institute and a lecturer at Johns Hopkins, where he teaches health care policy.
In addition to writing countless feature articles for the Monthly, Phil’s work has appeared in The Atlantic Monthly, The Financial Times, Foreign Affairs, Foreign Policy, Harvard Business Review, The New Republic, The New Statesman, The New York Times Magazine, Politica Exterior, Der Spiegel, and World Politics Review.
Formerly a senior writer and deputy assistant managing editor at U.S. News & World Report, Phillip has won many awards for his business and financial writing, including UCLA’s Gerald Loeb Award, and the top prize for investigative journalism from Investigative Reporters and Editors. He is a graduate of Oberlin College, and was also a Knight-Bagehot Fellow at Columbia University.
Phillip can be reached at: firstname.lastname@example.org
How America’s anti-monopoly laws got turned against the little guy.
Four giant health care systems are joining forces to produce generic drugs at a lower cost to themselves. But, that doesn’t mean the savings will be passed on to consumers.
A single-payer system will degenerate into corporate welfare unless we take on health care monopolies.
This time, the hapless New York Times is the culprit.
To save their party from Trumpism, Republicans need to once again take on monopolists.